Advanced Therapy Revolutionizes Atopic Dermatitis Market Prospects

The atopic dermatitis market size is expected to be valued at USD 15.42 Billion in 2024 and reach USD 30.5 Billion by 2029, growing at a CAGR of 14.5 % from 2024 to 2029.

Atopic dermatitis, known as eczema, is a prevalent skin condition marked by red, inflamed, and itchy skin. It is a chronic condition commonly seen in children but can also impact adults. Atopic dermatitis is thought to result from a mix of genetic, immune system, and environmental factors and is not contagious. Treatment typically includes moisturizing the skin, steering clear of triggers that exacerbate symptoms, and sometimes using prescription medications to alleviate inflammation and itching.

Global Atopic dermatitis Market Report Scope:
• Market Size (2029): USD 30.5 Billion
• Market Size (2024): USD 15.42 Billion
• CAGR (2024 to 2029): 14.5 %
• Base Year: 2023
• Forecast Period: 2024 to 2029
• Segments Analysed: By Treatment Type, Route of Administration, Distribution channel, and Region.
• Geographies Covered: North America, Europe, APAC, Latin America, and Middle East & Africa
• Key Market Players Profiled: Novartis International AG, Sanofi, Pfizer, AbbVie Pharmaceuticals Pvt Ltd, Bausch Health Cos., Inc., Bristol-Myers Squibb Corporation, Regeneron Pharma, Viatris Incorporation, LEO Pharma, and Dermavant Sciences. are playing a dominant role in the atopic dermatitis market.

Browse full details of the report @ https://www.marketdataforecast.com/market-reports/atopic-dermatitis-treatment-market

Key Insights from The Report:

• Based on Treatment Type, the drug treatment segment captured highest share of the global market in 2023.
• Based on Route of Administration, the topical segment dominated the market in 2023.
• Based on Distribution channel, the retail pharmacies segment occupied the majority of the global market share in 2023.

• North America dominated the healthcare analytics market in 2023. Europe accounted for second- highest share of the global atopic dermatitis market in 2023 and on the other hand, the Asia-Pacific region is estimated to grow at the fastest CAGR during the forecast period.
• AMD Global Atopic Dermatitis Market Novartis International AG, Sanofi, Pfizer, AbbVie Pharmaceuticals Pvt Ltd, Bausch Health Cos., Inc., Bristol-Myers Squibb Corporation, Regeneron Pharma, Viatris Incorporation, LEO Pharma, and Dermavant Sciences are dominated the atopic dermatitis market.

The increasing prevalence of atopic dermatitis, a chronic skin condition characterized by inflammation and itchiness, is driving the market growth. The ongoing advancements in drug development by researchers and pharmaceutical companies due to heavy investments are leading to the introduction of innovative therapies for atopic dermatitis, which is fueling the global market expansion. The advanced therapies, including biologics, topical steroids, and other novel treatments, offer improved patient outcomes and contribute to the market's expansion. According to TMR, a global market research company based in Wilmington, Delaware, the pharmaceutical industry is witnessing substantial investments in research and development for atopic dermatitis drugs. Biotechnology and pharmaceutical companies are focusing on developing novel therapeutic options such as targeted biologics, small molecule inhibitors, and immunomodulators. These innovative drugs are known for their enhanced efficacy and safety profiles, which drive their adoption and market growth. The COVID-19 pandemic has also played a role in the market's growth. The increased frequency of handwashing during the pandemic has led to cracked and dry skin, prone to infections among atopic dermatitis patients. This has resulted in a rise in the incidence of hand eczema due to constant exposure to oil-stripping soaps and handwash. These scenarios created an opportunity for market players to develop moisturizer-based creams and ointments, which led to enhancements in the global atopic dermatitis market size expansion. The high rate of disease recurrence has prompted companies to invest in developing novel biologics with high efficacy, which has fueled the adoption rate worldwide.

The high cost of newer treatments, such as biologics, can limit access for some patients and healthcare organizations, limiting market growth worldwide. The complexity of the disease often results in trial-and-error approaches to treatment, which can be difficult for both patients and healthcare providers. The need for awareness and understanding of atopic dermatitis among the general public and some healthcare professionals, leading to delays in diagnosis and treatment that impact patient outcomes, is impeding the market expansion. The regulatory approval process for new treatments can be lengthy and expensive, further delaying their availability to patients.

SEGMENTATION INCLUDED IN THIS REPORT:

By Treatment Type:
• Drug Treatment
• Radiation Treatment

By Route of Administration:
• Topical
• Oral

By Distribution Channel:
• Hospital pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region:
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Browse Regional Reports:

North America Atopic Dermatitis Market Research Report - Segmented By Treatment Type, Route of Administration, Distribution Channel and Country (U.S, Canada & Rest of North America) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2023 to 2028) -https://www.marketdataforecast.com/market-reports/north-america-atopic-dermatitis-treatment-market

Europe Atopic Dermatitis Market Research Report - Segmented By Treatment Type, Route of Administration, Distribution Channel and Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic and Rest of Europe) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2023 to 2028) - https://www.marketdataforecast.com/market-reports/europe-atopic-dermatitis-treatment-market

Asia Pacific Atopic Dermatitis Market Research Report - Segmented By Treatment Type, Route of Administration, Distribution Channel & Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore & Rest of APAC) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2023 to 2028) - https://www.marketdataforecast.com/market-reports/asia-pacific-atopic-dermatitis-treatment-market

Latin America Atopic Dermatitis Market Research Report - Segmented by Treatment Type, Route of Administration, Distribution Channel & Country (Mexico ,Brazil, Argentina, Chile and Rest of Latin America) - Industry Analysis, Size,Share, Growth, Trends, & Forecast (2023 to 2028) -https://www.marketdataforecast.com/market-reports/Latin-America-atopic-dermatitis-treatment-market

Middle East & Africa Atopic Dermatitis Market Research Report - Segmented by Treatment Type, Route of Administration, Distribution Channel & Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan and Rest of MEA) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast from (2023 to 2028 )- https://www.marketdataforecast.com/market-reports/middle-east-and-africa-topic-dermatitis-treatment-market

TABLE OF CONTENTS:

1. Introduction

1.1 Market Definition

1.2 Study Deliverables

1.3 Base Currency, Base Year and Forecast Periods

1.4 General Study Assumptions

2. Research Methodology

2.1 Introduction

2.2 Research Phases

2.2.1 Secondary Research

2.2.2 Primary Research

2.2.3 Econometric Modelling

2.2.4 Expert Validation

2.3 Analysis Design

2.4 Study Timeline

3. Overview

3.1 Executive Summary

3.2 Key Inferences

3.3 Epidemiology

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

4.1 Market Drivers

4.2 Market Restraints

4.3 Key Challenges

4.4 Current Opportunities in the Market

5. Market Segmentation

5.1 Treatment Type

5.1.1 Introduction

5.1.2 Drug Treatment

5.1.2.1 Emollients

5.1.2.2 Antihistamines

5.1.2.3 Antibiotics

5.1.2.4 Corticosteroids

5.1.2.5 Calcineurin Inhibitors

5.1.3 Radiation Treatment

5.1.4 Y-o-Y Growth Analysis, By Treatment Type

5.1.5 Market Attractiveness Analysis, By Treatment Type

5.1.6 Market Share Analysis, By Treatment Type

5.2 Route of administration

5.2.1 Introduction

5.2.2 Topical

5.2.3 Oral

5.2.4 Y-o-Y Growth Analysis, By Route of administration

5.2.5 Market Attractiveness Analysis, By Route of administration

5.2.6 Market Share Analysis, By Route of administration

5.3 Distribution Channel

5.3.1 Introduction

5.3.2 Hospital Pharmacies

5.3.3 Retail Pharmacies

5.3.4 Online Pharmacies

5.3.5 Y-o-Y Growth Analysis, By Distribution Channel

5.3.6 Market Attractiveness Analysis, By Distribution Channel

5.3.7 Market Share Analysis, By Distribution Channel

6. Geographical Analysis

6.1 Introduction

6.1.1 Regional Trends

6.1.2 Impact Analysis

6.1.3 Y-o-Y Growth Analysis

6.1.3.1 By Geographical Area

6.1.3.2 By Treatment Type

6.1.3.3 By Route of administration

6.1.3.4 By Distribution Channel

6.1.4 Market Attractiveness Analysis

6.1.4.1 By Geographical Area

6.1.4.2 By Treatment Type

6.1.4.3 By Route of administration

6.1.4.4 By Distribution Channel

6.1.5 Market Share Analysis

6.1.5.1 By Geographical Area

6.1.5.2 By Treatment Type

6.1.5.3 By Route of administration

6.1.5.4 By Distribution Channel

6.2 North America

6.2.1 Introduction

6.2.2 United States

6.2.3 Canada

6.3 Europe

6.3.1 Introduction

6.3.2 U.K

6.3.3 Spain

6.3.4 Germany

6.3.5 Italy

6.3.6 France

6.4 Asia-Pacific

6.4.1 Introduction

6.4.2 China

6.4.3 India

6.4.4 Japan

6.4.5 Australia

6.4.6 South Korea

6.5 Latin America

6.5.1 Introduction

6.5.2 Brazil

6.5.3 Argentina

6.5.4 Mexico

6.5.5 Rest of Latin America

6.6 Middle East & Africa

6.6.1 Introduction

6.6.2 Middle-East

6.6.3 Africa

7. Strategic Analysis

7.1 PESTLE analysis

7.1.1 Political

7.1.2 Economic

7.1.3 Social

7.1.4 Technological

7.1.5 Legal

7.1.6 Environmental

7.2 Porter's Five analysis

7.2.1 Bargaining Power of Suppliers

7.2.2 Bargaining Power of Consumers

7.2.3 Threat of New Entrants

7.2.4 Threat of Substitute Products and Services

7.2.5 Competitive Rivalry within the Industry

8. Market Leaders' Analysis

8.1 Astellas Pharma Inc.

8.1.1 Overview

8.1.2 Product Analysis

8.1.3 Financial analysis

8.1.4 Recent Developments

8.1.5 SWOT analysis

8.1.6 Analyst View

8.2 Sanofi S.A.

8.3 Valeant Pharmaceuticals International, Inc.

8.4 Novartis International AG

8.5 Pfizer Inc.

8.6 Meda Pharmaceuticals

8.7 Regeneron Pharmaceuticals Inc.

8.8 Anacor Pharmaceuticals, Inc.

9. Competitive Landscape

9.1 Market share analysis

9.2 Merger and Acquisition Analysis

9.3 Agreements, Collaborations, and Joint Ventures

9.4 New Product Launches

10. Market Outlook and Investment Opportunities

Appendix

a) List of Tables

b) List of Figures

Contact Us:
MarketDataForecast
www.marketdataforecast.com
Phone: +1-888-702-9626
Email: sales@marketdataforecast.com
5th Floor, Trendz Pride, Patrika Nagar Rd Number 1, HUDA Techno Enclave, HITEC City, Hyderabad, Telangana 500081, India

About Us:
Market Data Forecast is a firm working in the areas of market research, business intelligence and consulting. We have rich experience in research and consulting for various business domains to cater to the needs of both individual and corporate clients.

This release was published on openPR.